Phase II trial of fazarabine in advanced colorectal carcinoma.

Journal Article

A total of 15 patients with measurable advanced colorectal adenocarcinoma were prospectively treated with fazarabine (Ara-AC), reconstituted in dimethyl sulfoxide, and administered at a starting dose of 48 mg/m2/day as a continuous intravenous infusion for three days. The dose was repeated every 21 days and dose escalations or reductions were made on the basis of toxicities encountered in the preceding course. No patient achieved either a complete or partial response. Major toxicities encountered were granulocytopenia, thrombocytopenia, nausea, vomiting, anemia, and headache. All toxicities were reversible upon discontinuation of the drug and no life-threatening toxicities occurred. These data indicate that further clinical trials in colorectal carcinoma with this agent and schedule of administration are not warranted.

Full Text

Duke Authors

Cited Authors

  • Hubbard, KP; Daugherty, K; Ajani, JA; Pazdur, R; Levin, B; Abbruzzese, JL

Published Date

  • April 1, 1992

Published In

Volume / Issue

  • 10 / 1

Start / End Page

  • 39 - 42

PubMed ID

  • 1376722

Electronic International Standard Serial Number (EISSN)

  • 1573-0646

International Standard Serial Number (ISSN)

  • 0167-6997

Digital Object Identifier (DOI)

  • 10.1007/bf01275479

Language

  • eng